GlaxoSmithKline PLC Net Worth
GlaxoSmithKline PLC Net Worth Breakdown | GSK |
GlaxoSmithKline PLC Net Worth Analysis
GlaxoSmithKline PLC's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including GlaxoSmithKline PLC's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of GlaxoSmithKline PLC's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform GlaxoSmithKline PLC's net worth analysis. One common approach is to calculate GlaxoSmithKline PLC's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares GlaxoSmithKline PLC's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing GlaxoSmithKline PLC's net worth. This approach calculates the present value of GlaxoSmithKline PLC's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of GlaxoSmithKline PLC's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate GlaxoSmithKline PLC's net worth. This involves comparing GlaxoSmithKline PLC's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into GlaxoSmithKline PLC's net worth relative to its peers.
Enterprise Value |
|
To determine if GlaxoSmithKline PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlaxoSmithKline PLC's net worth research are outlined below:
| GlaxoSmithKline PLC generated a negative expected return over the last 90 days | |
| On 10th of October 2024 GlaxoSmithKline PLC paid $ 0.3857 per share dividend to its current shareholders | |
| Latest headline from washingtonexaminer.com: Big Pharma is pretty great, actually |
GlaxoSmithKline PLC Quarterly Good Will |
|
GlaxoSmithKline PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlaxoSmithKline PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know GlaxoSmithKline PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-09-30 | 4.1 M | Provident Trust Company | 2024-09-30 | 4 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | Hsbc Holdings Plc | 2024-06-30 | 3.6 M | Hotchkis & Wiley Capital Management Llc | 2024-09-30 | 3.5 M | Equity Investment Corp | 2024-09-30 | 3.5 M | Lmr Partners Llp | 2024-06-30 | 3.3 M | Camber Capital Management Llc | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Dodge & Cox | 2024-09-30 | 68.1 M | Fmr Inc | 2024-09-30 | 29 M |
Follow GlaxoSmithKline PLC's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 69.29 B.Market Cap |
|
Project GlaxoSmithKline PLC's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.19 | |
| Return On Capital Employed | 0.18 | 0.17 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.47 |
When accessing GlaxoSmithKline PLC's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures GlaxoSmithKline PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlaxoSmithKline PLC's profitability and make more informed investment decisions.
Evaluate GlaxoSmithKline PLC's management efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.0724 % which means that on every $100 spent on assets, it made $0.0724 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2185 %, implying that it generated $0.2185 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.17. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.16 | 3.32 | |
| Tangible Book Value Per Share | (2.17) | (2.06) | |
| Enterprise Value Over EBITDA | 8.08 | 7.68 | |
| Price Book Value Ratio | 4.40 | 8.65 | |
| Enterprise Value Multiple | 8.08 | 7.68 | |
| Price Fair Value | 4.40 | 8.65 | |
| Enterprise Value | 61.1 B | 44.8 B |
Leadership at GlaxoSmithKline PLC emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 2.1592 | Revenue 31.3 B | Quarterly Revenue Growth (0.02) | Revenue Per Share 15.38 | Return On Equity 0.2185 |
GlaxoSmithKline PLC Corporate Filings
6K | 22nd of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 15th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
GlaxoSmithKline PLC Earnings per Share Projection vs Actual
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.